Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June 18, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company...
Hence then, the article about oncoinvent announces positive final data from phase 1 2a trial of radspherin in patients with colorectal peritoneal metastases was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases )
Also on site :
- Prominent Canadian Musician Says Gig Was Cancelled After Google AI Overview Wrongly Branded Him Sex Pest
- Goldman Sachs expects layoffs to keep rising—and says investors are punishing the stocks of companies that slash staff
- Tuya Smart Launches "Hey Tuya:" A Super AI Life Assistant Bringing Physical AI to Everyday Life